Navigation Links
Growing Interest in Regenerative Medicine to Drive the Mesenchymal Stem Cells Market, According to a Soon to Be Released Report by Global Industry Analysts, Inc.
Date:12/5/2013

San Jose, CA (PRWEB) December 05, 2013

Follow us on LinkedIn – GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the “Mesenchymal Stem Cells (MSCs)” markets. The study will examine key drivers and trends impacting the market such as increased investments in MSC research; advances in autologous MSCs; rise in the number of patent applications in the field of human tissue regeneration; growing prominence of oncology, orthopedics, inflammatory disorders, and cardiology as lucrative therapeutic application areas; and growing interest in the use of MSCs for providing personalized cell therapy for autoimmune diseases.

A rapidly growing area of stem cell research, Mesenchymal Stem Cells (MSCs) are defined as progenitor cells capable of producing multiple types of specialized cells in the body such as, osteoblasts, chondrocytes, adipocytes, myocytes, and neuronal cells. MSCs reside in bone marrow and other tissues such as umbilical cord, fat and muscle tissues. Ability of MSCs to repair tissue damage is resulting in increased interest in MSC based research in the field of tissue engineering and regenerative medicine. The last few years have witnessed significant increase in the number of clinical studies focused on MSC based bone and cartilage repair, heart and blood vessel repair. With cellular therapies now emerging as the new frontier of modern medical treatment, MSCs based regenerative approaches to treating neurological diseases is expected to bring in new opportunities for growth in the market. Breakthrough developments in delivery of MSCs through intracerebral or intrathecal injections remain critical for successful commercialization of MSC-based cellular therapies for neurodegenerative disorders. The market is also expected to benefit from increased use of MSCs in cell-based screening assays, such as, siRNA screening and biomolecule screening. In addition, cutting edge developments in genetically engineered MSCs as delivery vehicles for treatment will largely influence future market growth.

Other promising application areas include use of MSCs as immunomodulators in treating graft-versus-host (GVHD) disease, preventing transplant rejection, to enhance islet transplantation success in treatment of type I diabetes, and as anti-cancer agents in cancer treatment. MSC-based cancer therapies especially are expected to witness strong R&D interest, given the tumor-trophic migratory properties of MSCs. The study estimates Mesenchymal Stem Cells (MSCs) to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Drug Developers, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Read the full story at http://www.prweb.com/releases/mesenchymal_stem_cells/stem_cells_research/prweb11395229.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
2. How the alphabet of data processing is growing: Research team generates flying qubits
3. New Approach to Growing Waste to Value Industry in United States
4. BioSpace Spotlights the growing Midwest Life Science Community
5. Enterologics Highlights Growing News on Probiotics on the Web
6. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
7. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
8. AllCells, LLC Named to Inc. Magazines 500/5000 List of Fastest Growing Companies
9. Breast cancer cells growing in 3D-matrix revert to normal
10. Ramey & Browning Announces New Location and New Hire Firm Is Well Positioned to Address Growing Client Needs In 2013
11. Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... ... February 03, 2016 , ... ... and Unix visualization solutions today announced the addition of a powerful “Session Preview” ... to see the current state of the remote Linux desktop or other applications ...
(Date:2/3/2016)... , Feb. 3, 2016  Silk Therapeutics, Inc., today announced ... Silk Therapeutics has now raised a total of $10.25 million ... the company. The Series A2 round was led by existing ... , with participation from new investors Lear Corporation and Highland ... Roy P. Disney ; Richard Sackler , MD, with ...
(Date:2/3/2016)... NY (PRWEB) , ... February 03, 2016 , ... ... new products to aid in the rapid development and ongoing quality control of ... Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... silicon (Si) and InGaAs chips and wafers, and InP epi wafers based in ... from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si and InGaAs PIN ...
Breaking Biology Technology:
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... , Jan. 6, 2016 Based ... market, Frost & Sullivan recognizes MorphoTrak, LLC, a ... North American Frost & Sullivan Company of the ... fingerprint scanning technology, Morpho Wave™ , has consolidated ... the fingerprint biometrics market. Morpho Wave is ...
Breaking Biology News(10 mins):